Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF

Leukemia Research

Volumn 35, Issue 1, 2011, Pages 87-94

  Smith, B Douglas ^a   Jones, Richard J ^a   Cho, Eunpi ^a   Kowalski, Jeanne ^a   Karp, Judith E ^a   Gore, Steven D ^a   Vala, Milada ^a   Meade, Brooke ^a   Baker, Sharyn D ^b   Zhao, Ming ^a   Piantadosi, Steven ^c   Zhang, Zhe ^a   Blumenthal, Gideon ^d   Warlick, Erica D ^e   Brodsky, Robert A ^a   Murgo, Anthony ^d   Rudek, Michelle A ^a   Matsui, William H ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bryostatin; Differentiation therapy; Drug resistance; Growth factors; Leukemia; Myelodysplastic syndrome

Indexed keywords

BRYOSTATIN 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; ATAXIA; CATHETER INFECTION; CELLULITIS; CHOLECYSTITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTINUOUS INFUSION; COUGHING; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DYSPHAGIA; DYSPNEA; ERYTHEMA MULTIFORME; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC MALIGNANCY; HEMOLYSIS; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INSOMNIA; MALE; MAXIMUM TOLERATED DOSE; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; MYALGIA; MYELODYSPLASTIC SYNDROME; MYOSITIS; NAUSEA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; POLYURIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SIDE EFFECT; STOMATITIS; SYNCOPE; TACHYCARDIA; THROMBOSIS; VOICE; WEAKNESS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRYOSTATINS; CELL DIFFERENTIATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 78650171369     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.06.001     Document Type: Article

References (30)

1. Pettit G.R., Herald C.L., Doubek D.L., et al. Anti-neoplastic agents. 86. Isolation and structure of bryostatin-1. J Am Chem Soc 1982, 104:6846-6848.
2. Berkow R.L., Kraft A.S. Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor. Biochem Biophys Res Commun 1985, 131:1109-1116.
3. Smith J.B., Smith L., Pettit G.R. Bryostatins - potent, new mitogens that mimic phorbol ester tumor promoters. Biochem Biophys Res Commun 1985, 132:939-945.
4. Stone R.M., Sariban E., Pettit G.R., Kufe D.W. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood 1988, 72:208-213.
5. Sharkis S.J., Leonard J.P., Ihle J.N., May W.S. The effects of interleukin-3, bryostatin and thymocytes on erythropoiesis. Ann NY Acad Sci 1989, 554:59-65.
6. Kraft A.S., William F., Pettit G.R., Lilly M.B. Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res 1989, 49:1287-1293.
7. Drexler H.G., Gignac S.M., Jones R.A., et al. Bryostatin-1 induces differentiation of B-chronic lymphocytic-leukemia cells. Blood 1989, 74:1747-1757.
8. May W.S., Sharkis S.J., Esa A.H., et al. Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. Proc Natl Acad Sci USA 1987, 84:8483-8487.
9. Vrana J.A., Saunders A.M., Chellappan S.P., Grant S. Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937). Differentiation 1998, 63:33-42.
10. Grant S., Pettit G.R., Howe C., McCrady C. Effect of the protein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor. Leukemia 1991, 5:392-398.
11. Matsui W.H., Gladstone D.E., Vala M.S., et al. The role of growth factors in the activity of pharmacological differentiation agents. Cell Growth Differ 2002, 13:275-283.
12. Matsui W., Smith B.D., Vala M., et al. Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia. Br J Haematol 2005, 128:853-862.
13. Petzer A.L., Eaves C.J., Barnett M.J., Eaves A.C. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood 1997, 90:64-69.
14. Angstreich G.R., Matsui W., Huff C.A., et al. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br J Haematol 2005, 130:373-381.
15. Jones R.J., Sharkis S.J., Miller C.B., et al. Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro. Blood 1990, 75:1319-1323.
16. O'Quigley J., Pepe M., Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990, 46:33-48.
17. Piantadosi S., Fisher J.D., Grossman S. Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother Pharmacol 1998, 41:429-436.
18. Cheson B.D., Bennett J.M., Kopecky K.J., et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21:4642-4649.
19. Cheson B.D., Bennett J.M., Kantarjian H., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96:3671-3674.
20. Carr M.E., Carr S.L., Grant S. A Sensitive platelet activation-based functional assay for the antileukemic agent bryostatin-1. Anti-Cancer Drugs 1995, 6:384-391.
21. Deng X.M., Ito T., Carr B., Mumby M., May W.S. Reversible phosphorylation of Bcl2 following interleukin 3 or bryostatin 1 is mediated by direct interaction with protein phosphatase 2A. J Biol Chem 1998, 273:34157-34163.
22. Al Katib A.M., Smith M.R., Kamanda W.S., et al. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 1998, 4:1305-1314.
23. Khan P., McGown A.T., Dawson M.J., et al. High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique. J Chromatogr B Biomed Sci Appl 1998, 709:113-117.
24. Schaufelberger D.E., Koleck M.P., Beutler J.A., et al. The large-scale isolation of bryostatin-1 from bugula-neritina following current good manufacturing practices. J Nat Prod 1991, 54:1265-1270.
25. Baer J.C., Slack J.A., Pettit G.R. Stability-indicating high-performance liquid chromatography assay for the anticancer drug bryostatin 1. J Chromatogr 1989, 467:332-335.
26. Zhao M., Rudek M.A., He P., Smith B.D., Baker S.D. Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometry. Anal Biochem 2005, 337:143-148.
27. Gibaldi M., Perrier D. Noncompartmental analysis based on statistical moment theory. Pharmacokinetics 1982, Marcel Dekker, New York, p. 409-17.
28. Lanotte M., Martin-Thouvenin V., Najman S., et al. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991, 77:1080-1086.
29. Marshall J.L., Bangalore N., El Ashry D., et al. Phase I study of prolonged infusion bryostatin-1 in patients with advanced malignancies. Cancer Biol Ther 2002, 1:409-416.
30. Haas N.B., Smith M., Lewis N., et al. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study. Clin Cancer Res 2003, 9:109-114.